Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

May 7, 2026

Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Read more

May 5, 2026

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.

Read more

April 30, 2026

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Read more

Upcoming event

August 21, 2026

Interim Report Q2 2026 webcast (10:00 am CEST)

Latest presentation

April 29, 2026

Interim report Q1 2026 (webcast)

Latest Report

April 29, 2026

Interim report Q1 2026

Calendar and upcoming reports

August 21, 2026 (7:00am CEST)

Interim Report Q2 2026

November 6, 2026 (7:00am CET)

Interim Report Q3 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]